Literature DB >> 29097089

Anti-HIV Passive Immunization: New Weapons in the Arsenal.

Ruth M Ruprecht1.   

Abstract

Anti-HIV passive immunization with human neutralizing monoclonal antibodies (nmAbs) has made exciting gains: (i) identification of the HIV envelope V2 apex as a new in vivo protective epitope, (ii) a novel clade C SHIV for challenge studies, and (iii) a highly protective, trispecific nmAb. Potent, broad-spectrum protection by nmAbs holds promise.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  broadly neutralizing monoclonal antibody; clade C SHIV; nonhuman primate models; passive immunization; trispecific neutralizing monoclonal antibody

Mesh：

Substances：

Year:  2017        PMID： 29097089      PMCID： PMC5701852          DOI： 10.1016/j.tim.2017.10.006

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN： 0966-842X            Impact factor:   17.079


  10 in total

1.  Specific and non-specific immunity and protection of macaques against SIV infection.

Authors:  R Le Grand; G Vogt; B Vaslin; P Roques; F Théodoro; A M Aubertin; D Dormont
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

2.  Fc receptor but not complement binding is important in antibody protection against HIV.

Authors:  Ann J Hessell; Lars Hangartner; Meredith Hunter; Carin E G Havenith; Frank J Beurskens; Joost M Bakker; Caroline M S Lanigan; Gary Landucci; Donald N Forthal; Paul W H I Parren; Preston A Marx; Dennis R Burton
Journal:  Nature       Date:  2007-09-06       Impact factor: 49.962

3.  Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env.

Authors:  R J Song; A-L Chenine; R A Rasmussen; C R Ruprecht; S Mirshahidi; R D Grisson; W Xu; J B Whitney; L M Goins; H Ong; P-L Li; E Shai-Kobiler; T Wang; C M McCann; H Zhang; C Wood; C Kankasa; W E Secor; H M McClure; E Strobert; J G Else; R M Ruprecht
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques.

Authors:  Ling Xu; Amarendra Pegu; Ercole Rao; Nicole Doria-Rose; Jochen Beninga; Krisha McKee; Dana M Lord; Ronnie R Wei; Gejing Deng; Mark Louder; Stephen D Schmidt; Zachary Mankoff; Lan Wu; Mangaiarkarasi Asokan; Christian Beil; Christian Lange; Wulf Dirk Leuschner; Jochen Kruip; Rebecca Sendak; Young Do Kwon; Tongqing Zhou; Xuejun Chen; Robert T Bailer; Keyun Wang; Misook Choe; Lawrence J Tartaglia; Dan H Barouch; Sijy O'Dell; John-Paul Todd; Dennis R Burton; Mario Roederer; Mark Connors; Richard A Koup; Peter D Kwong; Zhi-Yong Yang; John R Mascola; Gary J Nabel
Journal:  Science       Date:  2017-09-20       Impact factor: 47.728

5.  Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins.

Authors:  A Li; H Katinger; M R Posner; L Cavacini; S Zolla-Pazner; M K Gorny; J Sodroski; T C Chou; T W Baba; R M Ruprecht
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

6.  Characterization of a simian human immunodeficiency virus encoding the envelope gene from the CCR5-tropic HIV-1 Ba-L.

Authors:  Ranajit Pal; Brian Taylor; J Scott Foulke; Ruth Woodward; Michael Merges; Rob Praschunus; Andrew Gibson; Marvin Reitz
Journal:  J Acquir Immune Defic Syndr       Date:  2003-07-01       Impact factor: 3.731

7.  Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo.

Authors:  Brian Moldt; Eva G Rakasz; Niccole Schultz; Po-Ying Chan-Hui; Kristine Swiderek; Kimberly L Weisgrau; Shari M Piaskowski; Zachary Bergman; David I Watkins; Pascal Poignard; Dennis R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-25       Impact factor: 11.205

Review 8.  Engineering broadly neutralizing antibodies for HIV prevention and therapy.

Authors:  Casey K Hua; Margaret E Ackerman
Journal:  Adv Drug Deliv Rev       Date:  2016-01-29       Impact factor: 15.470

9.  Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge.

Authors:  Boris Julg; Lawrence J Tartaglia; Brandon F Keele; Kshitij Wagh; Amarendra Pegu; Devin Sok; Peter Abbink; Stephen D Schmidt; Keyun Wang; Xuejun Chen; M G Joyce; Ivelin S Georgiev; Misook Choe; Peter D Kwong; Nicole A Doria-Rose; Khoa Le; Mark K Louder; Robert T Bailer; Penny L Moore; Bette Korber; Michael S Seaman; Salim S Abdool Karim; Lynn Morris; Richard A Koup; John R Mascola; Dennis R Burton; Dan H Barouch
Journal:  Sci Transl Med       Date:  2017-09-06       Impact factor: 19.319

10.  Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity.

Authors:  Luzia M Mayr; Thomas Decoville; Sylvie Schmidt; Géraldine Laumond; Jéromine Klingler; Camille Ducloy; Seiamak Bahram; Susan Zolla-Pazner; Christiane Moog
Journal:  Sci Rep       Date:  2017-10-04       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.